The Global Policy Vacuum: Regulating CRISPR after Japan’s Breakthrough in Deleting Trisomy 21 from Down Syndrome Cells

In a major scientific development, researchers at Japan’s Mie University have successfully used CRISPR gene editing technology to delete the extra chromosome 21 from lab grown cells of individuals with Down syndrome. The edited cells demonstrated improved cellular function and normalized gene expression, marking a key milestone in the path toward potential genetic therapies for chromosomal conditions. Though not yet applicable to embryos or clinical treatment, the study raises urgent ethical and regulatory questions. This article explores the global policy gaps surrounding CRISPR’s use for conditions like Down syndrome, comparing national regulatory frameworks and ethical norms. It calls for an inclusive, internationally harmonized governance model that balances scientific progress with disability rights, reproductive autonomy, and anti-eugenics protections.